To Calculate Total Dose Delivered to Carcinoma Cervix Patients Treated with Volumetric Modulated Arc Therapy (VMAT) and Image-Guided Brachytherapy (IGBT)
DOI:
https://doi.org/10.51985/Keywords:
Cervical cancer, patients, population, Radiotherapy, VMAT, MRIAbstract
Abstract
Objective: To calculate the total radiation dose delivered to carcinoma cervix patients treated with Volumetric Modulated Arc Therapy (VMAT) and MRI-guided brachytherapy (IGBT), and to evaluate cumulative EQD2 to tumor and organs-atrisk.
Study Design and settings: This Descriptive, cross-sectional study was conducted at Department of Radiotherapy, INMOL Hospital, Lahore, from 1st August 2024 to 10th January 2025.
Methodology: Fifty patients with histologically confirmed carcinoma cervix, ECOG 0–II, aged 45–65 years, receiving VMAT-based external beam radiotherapy (45 Gy/25 fractions) followed by MRI-guided brachytherapy were included. EQD2 values for the high-risk target volume and organs-at-risk (bladder, rectum, sigmoid) were calculated using DVH parameters.
Results: The mean age of patients was 55.1 ± 5.8 years, with Stage IIIB being the most common stage (50%). A total of 64% received three brachytherapy insertions, while 36% required four. The mean cumulative tumor EQD2 was 84.9 ± 2.8 Gy. Mean bladder, rectum, and sigmoid EQD2 values were 78.1 ± 4.3 Gy, 67.3 ± 4.4 Gy, and 62.5 ± 4.2 Gy, respectively. More than 90% of patients met internationally recommended tumor and OAR dose constraints.
Conclusion: It is concluded that VMAT combined with MRI-guided brachytherapy delivers adequate cumulative tumor dose while maintaining organ-at-risk exposure within acceptable limits
References
1. World Health Organization. GLOBOCAN 2020: Cervical
Cancer. Estimated Incidence, Mortality and Prevalence
Worldwide in 2020 [Internet]. Available from: https://www.
thelancet.com/journals/langlo/article/PIIS2214-109X%2822
%29000501-0/fulltext
2. Speiser D, Mangler M, Köhler C, Hasenbein K, Herfel D,
Chintarvat Y, et al. Fertility outcome after vaginal radical
trachelectomy: a prospective study of 212 patients. Int J
Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011
Dec;21(9):1635–9.3. Lakhman Y, Akin O, Park KJ, Sarasohn DM, Zheng J,
Goldman DA, et al. Stage IB1 cervical cancer: role of
preoperative MR imaging in selection of patients for fertilitysparing radical trachelectomy. Radiology. 2013 Oct;269(1)
:149–58.
4. Malyapa RS, Mutic S, Low DA, Zoberi I, Bosch WR, Laforest
R, et al. Physiologic FDG-PET three-dimensional
brachytherapy treatment planning for cervical cancer. Int J
Radiat Oncol Biol Phys. 2002 Nov;54(4):1140–6.
5. Vinin N V., Jones J, Ajas VT, Muttath G, Suja CA, Yahyia
EKN, et al. Organ at risk doses during high-dose-rate
intracavitary brachytherapy for cervical cancer: A dosimetric
study. Int J Med Physics, Clin Eng Radiat Oncol. 2018;7(04):
472–8.
6. Wibowo RA, Haris B, Islamiyah DI. Dose evaluation of
organs at risk (OAR) cervical cancer using dose–volume
histogram (DVH) on brachytherapy. J Phys Conf Ser.
2017;853(1).
7. Gupta S, Maheshwari A, Parab P, Mahansthyet U, Hawaldar
R, Sastri Chopra S, et al. Neoadjuvant chemotherapy followed
by radical surgery versus concomitant chemoradiotherapy in
patients with stage IB2, IIA, or IIB squamous cervical cancer:
a randomized controlled trial. J Clin Oncol. 2018 Jun;36(16):
1548–55.
8. Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I,
Haie-Meder C, Fokdal LU, et al. MRI-guided adaptive
brachytherapy in locally advanced cervical cancer
(EMBRACE-I): a multicentre prospective cohort study. Lancet
Oncol. 2021 Apr;22(4):538–47.
9. Akiyama H, Pesznyák C, Béla D, Ferenczi Ö, Major T, Polgár
C, Takácsi-Nagy Z. Image guided high-dose-rate brachytherapy
versus volumetric modulated arc therapy for head and neck
cancer: A comparative analysis of dosimetry for target volume
and organs at risk. Radiol Oncol. 2018 Nov 12;52(4):461-
467. doi: 10.2478/raon-2018-0042. PMID: 30422804; PMCID:
PMC6287174.
10. Gazsi, I., Marcu, L.G. Comparative dosimetric assessment of
combined treatment modalities in cervical cancer radiotherapy
for optimal organ protection. Radiat Environ Biophys 64,
291–302 (2025). https://doi.org/10.1007/s00411-025-01113-
7
11. Van Anh DT, Thang VH, Dung TA, Huyen TT, Nhan DTT,
Van Giang B, Huyen PT. Outcome and toxicity of
chemoradiation using volumetric modulated arc therapy
followed by 3D image-guided brachytherapy for cervical
cancer: Vietnam National Cancer Hospital experience. Rep
Pract Oncol Radiother. 2024 Feb 16;28(6):784-793. doi:
10.5603/rpor.98735. PMID: 38515819; PMCID: PMC109
54271.
12. Hitova-Topkarova, D., Payakova, V., Yordanov, A., KostovaLefterova, D., Ivanova, M., Iliev, I., Valkov, M., Mutkurov,
N., Kostov, S., & Encheva, E. (2025). Preliminary Experience
with Electronic Brachytherapy in the Treatment of Locally
Advanced Cervical Carcinoma. Cancers, 17(14), 2286.
https://doi.org/10.3390/cancers17142286
13. Kim H, Lee YC, Benedict SH, Dyer B, Price M, Rong Y,
Ravi A, Leung E, Beriwal S, Bernard ME, Mayadev J, Leif
JRL, Xiao Y. Dose Summation Strategies for External Beam
Radiation Therapy and Brachytherapy in Gynecologic
Malignancy: A Review from the NRG Oncology and NCTN
Medical Physics Subcommittees. Int J Radiat Oncol Biol
Phys. 2021 Nov 15;111(4):999-1010. doi: 10.1016/j.ijrobp.
2021.06.019. Epub 2021 Jun 17. PMID: 34147581; PMCID:
PMC8594937.
14. van Heerden LE, Houweling AC, Koedooder K, van Kesteren
Z, van Wieringen N, Rasch CRN, Pieters BR, Bel A. Structurebased deformable image registration: Added value for dose
accumulation of external beam radiotherapy and brachytherapy
in cervical cancer. Radiother Oncol. 2017 May;123(2):319-
324. doi: 10.1016/j.radonc.2017.03.015. Epub 2017 Mar 31.
PMID: 28372889.
15. Xue J, Wu M, Zhang J, Yang J, Lv G, Qu B, Zhang Y, Yan
X, Song J. Delta-radiomics analysis based on magnetic
resonance imaging to identify radiation proctitis in patients
with cervical cancer after radiotherapy. Front Oncol. 2025
Jan 29;15:1523567. doi: 10.3389/fonc.2025.1523567. PMID:
39944831; PMCID: PMC11813761.
16. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al.
Cancer incidence and mortality in China, 2022. J Natl Cancer
Cent. 2024;4:47–53. doi:10.1016/j.jncc.2024.01.006
17. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, LaubySecretan B, et al. Global estimates of incidence and mortality
of cervical cancer in 2020: a baseline analysis of the WHO
Global Cervical Cancer Elimination Initiative. Lancet Glob
Health. 2023;11:e197–206. doi:10.1016/S2214-109X(22)
00501-0
18. Hafiz A, Abbasi AN, Ali N, Khan KA, Qureshi BM. Frequency
and severity of acute toxicity of pelvic radiotherapy for
gynecological cancer. J Coll Physicians Surg Pak. 2015;25:
802–6.
19. Le VH, Kha QH, Hung TNK, Le NQK. Risk score generated
from CT-based radiomics signatures for overall survival
prediction in non-small cell lung cancer. Cancers. 2021;13(14):
3616. doi:10.3390/cancers13143616
20. Le VH, Kha QH, Minh TNT, Nguyen VH, Le VL, Le NQK.
Development and validation of CT-based radiomics signature
for overall survival prediction in multi-organ cancer. J Digit
Imaging. 2023;36:911–22. doi:10.1007/s10278-023-00778-
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sana Naeem, Ayesha Anees, Ahmad Farooq, Tahir Sheikh, Rub Nawaz Maken (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
